Contact Us

The Future of Cancer Screening

20/20 GeneSystems pioneers innovative bio-testing and cancer diagnostic tools that address compelling unmet needs. 20/20’s digital diagnostics business develops and commercializes A.I powered cancer screenings tests deliver better tools to improve early detection of the most common cancers globally. Our emergency bio-detection business includes our patented BioCheck which is widely used by emergency responders. We are now distributing a rapid test kit for Covid-19, called  CoronaCheck.

We are believed to be the first company to launch a multi-cancer screening test powered by machine learning and large amounts of realworld.

Investor Information

Our Mission​

20/20 GeneSystems is a digital diagnostics company with the core mission of reducing cancer mortality in the U.S. and around the world through early detection. We believe in developing cutting edge solutions through combining innovation with well researched established procedures.

20/20 GeneSystems

About us

20/20 GeneSystems a U.S. based digital diagnostics company that harnesses the power of A.I. and big data analytics to reduce cancer mortality around the world through early detection. We have created innovative tests built around our proprietary algorithms to detect more than 6 common cancers. In the US, we also operate our own CLIA certified laboratory, catering to the needs of US consumers in our home market. We currently operate globally through partners, in Asia, the Middle East and Europe.

20/20 also has a proud history spanning almost 20 years of assisting first responders through innovative cancer screening as well as other biotech products.

Investors welcome!

20/20 GeneSystems is a US based private corporation located in Maryland.  Investment opportunities are currently available and as a Reg A+ company, anyone can become a shareholder in our company as well and we have raised more then $5m in equity crowd funding, making us one of the most successful crowd-funding life science companies in history. Additional opportunities are available for traditional accredited investors, family offices, private equity and venture capital firms. While our operations are global today our biggest markets are the United States and Asia.

Invest Now
Learn more

Our Products

OneTestTM is among the first multi-cancer screening panels to harness the power of Ai to improve the accuracy and usefulness of affordable tumor marker tests to help identify 6 or more types of cancer. OneTest is available in the US through our CLIA lab or internationally as a SAAS solution for health screening clinics.
PAULA’s TestTM is meant for use in patients at high risk of lung cancer due to long term smoking. PAULA’s Test can help detect lung cancer in patients without symptoms, even at the earliest stages. PAULAs test is more than just a lab test. It uses an Ai and clinical factors to generate the most accurate lung cancer risk profile available.
BioCheck® Suspicious Powder Screening Kit provides a cost effective, reliable, screening tool to quickly and easily determine whether a powder contains biological material in order to rule out many of the substances that cause powder incidents (e.g. talcum powder, dry wall dust, powdered sugar, etc.
CoronaCheckTM are rapid tests for the Novel Coronavirus (COVID-19) that delivers a result in ~10 minutes. The mechanism of action is the qualitative detection of IgM and IgG antibodies to SARS-CoV-2 using a fingerstick blood specimen as an aid in the determination of exposure to SARS-CoV-2 virus.
Learn more
Learn more
Learn more
Learn more

Grants & Awards

Contact Us

We would love to hear from you. Please complete the form below and we will get back to you as soon as possible.

20/20 GeneSystems (“20/20”) is focused on on reducing cancer deaths worldwide through its years of experience in the development and use of cancer biomarker test development.

Linkedin Facebook-f

Products

Company

Contact Us